US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

29.49

-0.8900-2.93%

Volume:462.15K

Turnover:13.59M

Market Cap:1.47B

PE:-10.37

High:30.40

Open:30.40

Low:28.80

Close:30.38

52wk High:53.65

52wk Low:6.71

Shares:49.71M

Float Shares:29.16M

Volume Ratio:0.35

T/O Rate:1.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8431

EPS(LYR):-3.0510

ROE:-47.52%

ROA:-28.01%

PB:4.13

PE(LYR):-9.67

Loading ...

Overview Company News Filings

Maze Therapeutics announces positive Phase 2 HORIZON topline data; week 12 uACR drops 35.6% in broad APOL1-mediated kidney disease patients

Maze Therapeutics Inc - to Advance Mze829 to Pivotal Program in Amkd

THOMSON REUTERS

Maze Therapeutics Inc - 50% of Patients Achieve >30% Uacr Reduction; Mze829 Well-Tolerated

THOMSON REUTERS

Maze Therapeutics Announces Positive Topline Data From Phase 2 Horizon Trial of Mze829 Demonstrating the First Clinical Proof-of-Concept in Patients With Broad Apol1-Mediated Kidney Disease

THOMSON REUTERS

Maze Therapeutics Inc Q4 Pretax Profit USD -34.568 Million VS. Ibes Estimate USD -34.7 Million

THOMSON REUTERS

Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 735,106 in common shares

Maze Therapeutics Initiated at Buy by Truist Securities

Maze Therapeutics Is Maintained at Outperform by Wedbush

Wedbush Raises Price Target on Maze Therapeutics to $58 From $43, Keeps Outperform Rating

MT Newswires Live

Maze Therapeutics Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $97

THOMSON REUTERS

Mizuho Securities Initiates Maze Therapeutics at Outperform With $97 Price Target

MT Newswires Live

Maze Therapeutics initiated with an Outperform at Mizuho

U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx

Maze Therapeutics Price Target Maintained With a $46.00/Share by BTIG

Maze Therapeutics, Inc. (MAZE) Gets a Buy from Leerink Partners

Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside

Maze Therapeutics Is Maintained at Buy by Guggenheim

Maze Therapeutics SVP Finance Amy Bachrodt Disposes of Common Shares

Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MAZE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":29.49,"timestamp":1774889634355,"preClose":30.38,"halted":0,"volume":462152,"delay":0,"changeRate":-0.029295589203423324,"floatShares":29160400,"shares":49708658,"eps":-2.8431,"marketStatus":"Trading","change":-0.89,"latestTime":"03-30 12:53:58 EDT","open":30.4,"high":30.4,"low":28.8,"amount":13589822.1898,"amplitude":0.052666,"askPrice":29.53,"askSize":202,"bidPrice":29.45,"bidSize":73,"shortable":3,"etf":0,"ttmEps":-2.8431,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774900800000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":30.38,"preHourTrading":{"tag":"盘前","latestPrice":30.25,"preClose":30.38,"latestTime":"09:25 EDT","volume":357,"amount":10581.79059,"timestamp":1774877100122,"change":-0.13,"changeRate":-0.004279,"amplitude":0.04345},"postHourTrading":{"tag":"盘后","latestPrice":30.38,"preClose":30.38,"latestTime":"18:39 EDT","volume":3518,"amount":106871.94,"timestamp":1774651191638,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.346574,"impliedVol":0.7037,"impliedVolPercentile":0.4627},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":29160400,"roa":"-28.01%","roe":"-47.52%","lyrEps":-3.051003,"volumeRatio":0.346574,"shares":49708658,"dividePrice":0,"high":30.4,"amplitude":0.052666,"preClose":30.38,"low":28.8,"week52Low":6.71,"pbRate":"4.13","week52High":53.65,"institutionHeld":0,"latestPrice":29.49,"committee":-0.469091,"eps":-2.8431,"divideRate":0,"volume":462152,"delay":0,"ttmEps":-2.8431,"open":30.4,"prevYearClose":41.43,"prevWeekClose":30.38,"prevMonthClose":45.59,"prevQuarterClose":41.43,"fiveDayClose":49,"twentyDayClose":45.61,"sixtyDayClose":41.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-25","symbol":"MAZE","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"pre","actualEps":-0.65},{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77},{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1773806400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-03-27","current":-10.685519,"percent":0.32069,"low":-19.775245,"twenty":-15.550091,"median":-5.100375,"eighty":9.693343,"high":14.99285,"avg":-2.482164,"sd":11.963594,"marketCap":1576261545},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065},{"date":"2026-01-23","current":-17.625471,"twenty":-12.065201,"median":7.127309,"eighty":10.196366,"marketCap":2223118312},{"date":"2026-01-30","current":-17.167667,"twenty":-12.419472,"median":6.955415,"eighty":10.162555,"marketCap":2165374980},{"date":"2026-02-06","current":-16.767088,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"marketCap":2114849563},{"date":"2026-02-13","current":-17.945934,"twenty":-14.175152,"median":6.511006,"eighty":10.056348,"marketCap":2263538645},{"date":"2026-02-20","current":-17.182927,"twenty":-14.401765,"median":6.360075,"eighty":9.954897,"marketCap":2167299757},{"date":"2026-02-27","current":-17.48813,"twenty":-14.737488,"median":-4.831743,"eighty":9.883564,"marketCap":2205795312},{"date":"2026-03-06","current":-17.282118,"twenty":-15.149512,"median":-4.864415,"eighty":9.832206,"marketCap":2179810813},{"date":"2026-03-13","current":-19.775245,"twenty":-15.332634,"median":-4.897086,"eighty":9.697287,"marketCap":2494271379},{"date":"2026-03-20","current":-18.857728,"twenty":-15.469975,"median":-4.962429,"eighty":9.697287,"marketCap":2378544116},{"date":"2026-03-27","current":-12.021519,"twenty":-15.550091,"median":-5.100375,"eighty":9.693343,"marketCap":1576261545}],"updateTime":1774871078141},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622221027","title":"Maze Therapeutics announces positive Phase 2 HORIZON topline data; week 12 uACR drops 35.6% in broad APOL1-mediated kidney disease patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2622221027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622221027?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436419,"startTime":"0","endTime":"0","summary":"Maze Therapeutics announces positive Phase 2 HORIZON topline data; week 12 uACR drops 35.6% in broad APOL1-mediated kidney disease patients. Maze Therapeutics announced positive topline data from the Phase 2 open-label HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease.At week 12, treatment with MZE829 drove a 35.6% mean uACR reduction, and 50% of patients achieved a greater than 30% reduction in uACR.Among AMKD patients with focal segmental glomerulosclerosis, uACR fell 61.8% on average, while non-diabetic AMKD patients saw a 48.6% mean reduction from baseline.In the safety-evaluable population , no serious adverse events or severe treatment-related adverse events were observed, and the most common treatment-related adverse events were headache (n=2) and diarrhea (n=2).The company said it expects to continue enrollment and advance MZE829 into a pivotal program, with HORIZON data planned for presentatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLnyKrn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2V16.EUR","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210149790.SGD","MAZE","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4007","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112"],"gpt_icon":0},{"id":"2622260027","title":"Maze Therapeutics Inc - to Advance Mze829 to Pivotal Program in Amkd","url":"https://stock-news.laohu8.com/highlight/detail?id=2622260027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622260027?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7PHY8J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2622202724","title":"Maze Therapeutics Inc - 50% of Patients Achieve >30% Uacr Reduction; Mze829 Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2622202724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622202724?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7PHY8J:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2622027287","title":"Maze Therapeutics Announces Positive Topline Data From Phase 2 Horizon Trial of Mze829 Demonstrating the First Clinical Proof-of-Concept in Patients With Broad Apol1-Mediated Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027287?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7PHY8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2622027252","title":"Maze Therapeutics Inc Q4 Pretax Profit USD -34.568 Million VS. Ibes Estimate USD -34.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027252?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nPLX99C684:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2622027703","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027703","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027703?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436400,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT. Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026. Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors. Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. \"We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today's positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,\" said Jason Coloma, Ph.D., chief executive officer of Maze. \"We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials of MZE782 in PKU and CKD. As we continu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIT","BK4555","03160","BK4588","FSGS","BK4604","TM","BK4585","BK4007","MAZE","BK4099"],"gpt_icon":0},{"id":"2621483757","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 735,106 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621483757","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621483757?lang=en_us&edition=fundamental","pubTime":"2026-03-21 06:50","pubTimestamp":1774047045,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & CMO at Maze Therapeutics, reported transactions in common stock dated 03/20/2026.An option exercise resulted in the acquisition of 15,000 shares at USD 10.42 per share.Sales totaling 6,161 shares were reported at a weighted average price of USD 48.2 per share.Additional sales included 3,795 shares at USD 49.32 per share and 5,044 shares at USD 50.02 per share.Following the reported transactions, Harold Bernstein beneficially owned 0 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL9xy5fn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 735,106 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2620234788","title":"Maze Therapeutics Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620234788?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:24","pubTimestamp":1773829440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 06:24 ET (10:24 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2619468031","title":"Maze Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468031","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468031?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:36","pubTimestamp":1773664560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 08:36 ET (12:36 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2619545716","title":"Wedbush Raises Price Target on Maze Therapeutics to $58 From $43, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545716","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545716?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:23","pubTimestamp":1773660238,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $58.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2618193900","title":"Maze Therapeutics Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $97","url":"https://stock-news.laohu8.com/highlight/detail?id=2618193900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618193900?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:33","pubTimestamp":1773138784,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY13I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2618394789","title":"Mizuho Securities Initiates Maze Therapeutics at Outperform With $97 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2618394789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618394789?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:27","pubTimestamp":1773138458,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $57.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","MAZE"],"gpt_icon":0},{"id":"2618338679","title":"Maze Therapeutics initiated with an Outperform at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2618338679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618338679?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:45","pubTimestamp":1773132319,"startTime":"0","endTime":"0","summary":"Mizuho initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $97 price target The firm says Maze’s first two drug candidate ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-outperform-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-outperform-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","MFG"],"gpt_icon":0},{"id":"2618984183","title":"U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx","url":"https://stock-news.laohu8.com/highlight/detail?id=2618984183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618984183?lang=en_us&edition=fundamental","pubTime":"2026-03-10 15:23","pubTimestamp":1773127423,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx March 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY0IY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","DNTH","FSS","CRWD","GO","CELC","ALEC","HIMY","PSTG","CDE","AAOI","KFY","GTLB","IE00B7SZL793.SGD","CHWY","ARCB","CROX","HMYY","ADBG","CASY","LU1941712264.USD","CCC","BETA","AMGN","BYRN","FIGR","FIVE","IE00B19Z6F94.USD","GILD","MGNX","FCEL","HIMS","HIYY","BIOA","LRCU","BBIO","MAZE","ADEA","HCA","LRCX","DOW","HIMZ","CRWL","HPE","NXT","CLYM","FDX","TGT","ADBE"],"gpt_icon":1},{"id":"2618479326","title":"Maze Therapeutics Price Target Maintained With a $46.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2618479326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618479326?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:34","pubTimestamp":1773052440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:34 ET (10:34 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2617636825","title":"Maze Therapeutics, Inc. (MAZE) Gets a Buy from Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636825","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636825?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:35","pubTimestamp":1772807756,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Maze Therapeutics, Inc., with a price target of $50.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-leerink-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2617546193","title":"Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2617546193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617546193?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:16","pubTimestamp":1772709406,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $60.00. Ananda Ghosh has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-maze-therapeutics-favorable-horizon-phase-2-setup-validated-apol1-biology-and-underappreciated-pipeline-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-maze-therapeutics-favorable-horizon-phase-2-setup-validated-apol1-biology-and-underappreciated-pipeline-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2616553729","title":"Maze Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553729","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616553729?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:32","pubTimestamp":1772631120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 08:32 ET (13:32 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2616377204","title":"Maze Therapeutics SVP Finance Amy Bachrodt Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616377204","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616377204?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:27","pubTimestamp":1772576866,"startTime":"0","endTime":"0","summary":"Amy Bachrodt, SVP, Finance at Maze Therapeutics, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL8YQCtx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics SVP Finance Amy Bachrodt Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2613947718","title":"Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2613947718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613947718?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:16","pubTimestamp":1771931819,"startTime":"0","endTime":"0","summary":"Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc. and keeping the price target at $60.00. Ananda Ghosh h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-maze-therapeutics-driven-by-mze829s-differentiated-apol1-mechanism-and-horizon-uacr-reduction-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-maze-therapeutics-driven-by-mze829s-differentiated-apol1-mechanism-and-horizon-uacr-reduction-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":85,"code":"91000000","status":"200"}]}}